Evidence map›Paper›PMID 33901176›Full record

ArticlePLoS biology2021

The dominantly expressed class II molecule from a resistant MHC haplotype presents only a few Marek's disease virus peptides by using an unprecedented binding motif.

Samer Halabi, Michael Ghosh, Stefan Stevanović, Hans-Georg Rammensee, Luca D Bertzbach, Benedikt B Kaufer, Martin C Moncrieffe, Bernd Kaspers, Sonja Härtle, Jim Kaufman

Open access · goldAbstract read
In one paragraph

Article in PLoS biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Samer HalabiUniversity of Cambridge, Department of Pathology, Cambridge, United Kingdom.ORCID 0000-0002-4612-5234
Michael GhoshUniversity of Tübingen, Department of Immunology, Institute of Cell Biology, Tübingen, Germany.ORCID 0000-0001-5550-9531
Stefan StevanovićUniversity of Tübingen, Department of Immunology, Institute of Cell Biology, Tübingen, Germany.ORCID 0000-0003-1954-7762
Hans-Georg RammenseeUniversity of Tübingen, Department of Immunology, Institute of Cell Biology, Tübingen, Germany.
Luca D BertzbachFreie Universität Berlin, Institut für Virologie, Berlin, Germany.ORCID 0000-0002-0698-5395
Benedikt B KauferFreie Universität Berlin, Institut für Virologie, Berlin, Germany.ORCID 0000-0003-1328-2695
Martin C MoncrieffeUniversity of Cambridge, Department of Biochemistry, Cambridge, United Kingdom.
Bernd KaspersLudwig Maximillians University, Veterinary Faculty, Planegg, Germany.ORCID 0000-0002-4447-3251
Sonja HärtleLudwig Maximillians University, Veterinary Faculty, Planegg, Germany.ORCID 0000-0002-7957-7827
Jim KaufmanUniversity of Cambridge, Department of Pathology, Cambridge, United Kingdom.ORCID 0000-0002-7216-8422
University of Cambridge · GBUniversity of Tübingen · DEFreie Universität Berlin · DE

Funding

Wellcome Trust 110106/Z/15/Z
6 · The paper itself

Abstract

Viral diseases pose major threats to humans and other animals, including the billions of chickens that are an important food source as well as a public health concern due to zoonotic pathogens. Unlike humans and other typical mammals, the major histocompatibility complex (MHC) of chickens can confer decisive resistance or susceptibility to many viral diseases. An iconic example is Marek's disease, caused by an oncogenic herpesvirus with over 100 genes. Classical MHC class I and class II molecules present antigenic peptides to T lymphocytes, and it has been hard to understand how such MHC molecules could be involved in susceptibility to Marek's disease, given the potential number of peptides from over 100 genes. We used a new in vitro infection system and immunopeptidomics to determine peptide motifs for the 2 class II molecules expressed by the MHC haplotype B2, which is known to confer resistance to Marek's disease. Surprisingly, we found that the vast majority of viral peptide epitopes presented by chicken class II molecules arise from only 4 viral genes, nearly all having the peptide motif for BL2*02, the dominantly expressed class II molecule in chickens. We expressed BL2*02 linked to several Marek's disease virus (MDV) peptides and determined one X-ray crystal structure, showing how a single small amino acid in the binding site causes a crinkle in the peptide, leading to a core binding peptide of 10 amino acids, compared to the 9 amino acids in all other reported class II molecules. The limited number of potential T cell epitopes from such a complex virus can explain the differential MHC-determined resistance to MDV, but raises questions of mechanism and opportunities for vaccine targets in this important food species, as well as providing a basis for understanding class II molecules in other species including humans.

Indexed as

Histocompatibility Antigens Class IIAnimalsAntigen PresentationB-LymphocytesBursa of FabriciusCells, CulturedChickensDisease ResistanceHaplotypesHerpesvirus 2, GallidImmunodominant EpitopesMarek DiseaseModels, MolecularPeptidesPoultry DiseasesViral ProteinsHistocompatibility Antigens Class IIImmunodominant EpitopesPeptidesViral Proteins

Identifiers

PMID33901176
PMCPMC8101999
OpenAlexW3159326274

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.